多分次放射外科治疗2级(WHO)高危脑膜瘤:一项II期临床试验
本研究为单中心、单臂II期探索性试验,纳入24例次全切除后复发或残留的2级(WHO 2016)脑膜瘤患者,评估辅助多分次放射外科的安全性(主要终点)及肿瘤局部控制(次要终点)。中位随访28个月,3年无进展生存率(含野内和野外进展)为47%,仅野内进展时为86%,末次随访局部控制率92%,仅1例(4.1%)出现2级治疗相关不良事件。
要点
- 24例高危2级脑膜瘤患者接受多分次放射外科,22例为28 Gy/4次,2例为24 Gy/4次。
- 中位随访28个月,8例(33.3%)出现疾病进展,含野内或野外进展。
- 3年无进展生存率(含野内和野外)为47%(95%CI 22-69%),仅野内为86%(95%CI 55-96%)。
核心结论
- 多分次放射外科对肿瘤体积提供良好的局部控制,且毒性发生率低;作者认为这些结果需要进一步研究以确认高危脑膜瘤患者的良好结局。
研究设计与样本
- II期探索性、单中心、单臂研究,纳入2017年4月至2019年5月招募的24例患者,年龄>18岁,组织学确诊的颅内复发或残留2级脑膜瘤(WHO 2016),KPS>70,排除NF2、合并肿瘤或妊娠患者。
主要发现
- 24例患者均接受多分次放射外科:22例接受28 Gy分4次,2例接受24 Gy分4次。
- 治疗相关不良事件(CTCAE 4.3)仅限于2级,发生于1例患者(4.1%)。
- 中位随访28个月,8例患者(33.3%)出现疾病进展,包括相对于计划靶区的野内或野外进展。
- 含野内和野外进展,3年无进展生存率为47%(95%CI 22-69%);仅计野内进展,3年无进展生存率为86%(95%CI 55-96%)。
- 末次随访时局部控制率为92%。
局限性
- 原文在结论中提出这些结果需要进一步研究以确认高危脑膜瘤患者的良好结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients suffering from recurrent and residual grade 2 (WHO) meningiomas after subtotal excision should be considered as high-risk groups with an uncertain prognosis. Adjuvant radiotherapy seems to be the best approach to reduce disease progression. The primary aim of this phase II explorative, monocentric, single arm study was to evaluate the safety of adjuvant multisession radiosurgery (mRS) in this group of patients; the efficacy in terms of tumour local control was the secondary endpoint. METHODS: Patients recruited from April 2017 to May 2019 were over 18 years old, had a histologically-documented intracranial recurrent or residual Grade 2 meningioma (WHO 2016) and a KPS > 70. Patients with NF2, concomitant neoplasm or pregnancy were excluded. Descriptive statistics were provided for categorical variables. Progression free survival (PFS) was modelled using the Kaplan-Meier method. RESULTS: Twenty-four patients were enrolled. All 24 patients underwent mRS: twenty-two patients received 28 Gy in 4 fractions, 2 patients received 24 Gy in 4 Treatment related adverse events (CTCAE 4.3) were limited to grade 2 in 1 patient (4.1%). At a median follow-up of 28 months, 8 patients (33.3%) had disease progression, either out-of-field or infield, compared with the planning target volume. Considering both infield and out-of-field progressions, 3-year PFS was 47% (95% confidence interval, CI, 22-69%); considering only the infield ones, 3-year PFS was 86% (95% CI 55-96%), and local control at last follow-up was 92%. CONCLUSION: mRS provides good local control of the tumour volume (TV) and is associated with a low rate of toxicity. These results call for further investigation to confirm favourable outcomes in patients with high-risk meningioma. TRIAL INFORMATION: NCT05081908, October 18, 2021, retrospectively registered.
引用
- Marchetti M, Pinzi V, Iezzoni C, et al. Multisession radiosurgery for grade 2 (WHO), high risk meningiomas. A phase II clinical trial. J Neurooncol. 2022. PMID: 35378640. doi:10.1007/s11060-022-03978-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。